CRIS Current Research Information System

CLISSA, CRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.259
NA - Nord America 2.255
EU - Europa 1.949
AF - Africa 198
Continente sconosciuto - Info sul continente non disponibili 111
SA - Sud America 92
OC - Oceania 2
Totale 6.866
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.184
SG - Singapore 653
CN - Cina 620
VN - Vietnam 518
GB - Regno Unito 454
IT - Italia 422
SE - Svezia 297
DE - Germania 213
HK - Hong Kong 126
IN - India 106
FR - Francia 99
RU - Federazione Russa 90
BR - Brasile 63
IE - Irlanda 58
NL - Olanda 56
KR - Corea 55
GR - Grecia 48
TG - Togo 46
SC - Seychelles 43
BD - Bangladesh 42
CA - Canada 41
ZA - Sudafrica 41
FI - Finlandia 35
NG - Nigeria 34
EE - Estonia 30
UA - Ucraina 30
JP - Giappone 22
JO - Giordania 21
AT - Austria 20
BE - Belgio 19
CH - Svizzera 19
HR - Croazia 19
CI - Costa d'Avorio 18
BG - Bulgaria 17
AR - Argentina 14
MX - Messico 13
PH - Filippine 12
IR - Iran 10
MY - Malesia 9
ES - Italia 7
PL - Polonia 7
TH - Thailandia 7
TM - Turkmenistan 7
MU - Mauritius 6
PK - Pakistan 6
TR - Turchia 6
EC - Ecuador 5
ID - Indonesia 5
IL - Israele 5
LT - Lituania 5
BB - Barbados 4
SA - Arabia Saudita 4
TW - Taiwan 4
AZ - Azerbaigian 3
CR - Costa Rica 3
IQ - Iraq 3
LB - Libano 3
OM - Oman 3
PY - Paraguay 3
UZ - Uzbekistan 3
CY - Cipro 2
EG - Egitto 2
ET - Etiopia 2
JM - Giamaica 2
KE - Kenya 2
KG - Kirghizistan 2
PE - Perù 2
TN - Tunisia 2
UY - Uruguay 2
AU - Australia 1
BS - Bahamas 1
BZ - Belize 1
CO - Colombia 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GI - Gibilterra 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
KH - Cambogia 1
LU - Lussemburgo 1
MA - Marocco 1
MK - Macedonia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
QA - Qatar 1
SO - Somalia 1
TT - Trinidad e Tobago 1
VE - Venezuela 1
Totale 6.755
Salva come PNG Salva come JPEG
Città #
Singapore 475
Southend 418
Ashburn 245
Chandler 197
Fairfield 180
Santa Clara 148
Hefei 138
Hong Kong 121
Bologna 117
San Jose 108
Beijing 92
Houston 92
Woodbridge 92
Wilmington 90
Ho Chi Minh City 85
Dong Ket 82
Seattle 80
Ann Arbor 78
Hanoi 77
Princeton 73
Cambridge 67
Milan 63
Dublin 58
Boardman 51
Lomé 46
Seoul 44
Westminster 40
Padova 37
Nanjing 36
New York 35
Lauterbourg 33
Helsinki 29
Saint Petersburg 27
Abeokuta 26
Los Angeles 24
Medford 24
Amman 21
Frankfurt am Main 21
Abidjan 18
Brussels 18
Buffalo 18
Jinan 18
Berlin 17
Council Bluffs 17
Sofia 17
Changsha 16
Shenyang 16
Tokyo 16
Turin 16
Bern 15
Dallas 15
Jiaxing 14
Redwood City 14
Vienna 14
Bengaluru 13
Da Nang 13
Shanghai 13
Athens 12
Haiphong 12
Hebei 12
Montreal 12
Munich 12
Nanchang 12
Redondo Beach 12
Rome 11
Toronto 11
Bremen 10
Florence 10
Jacksonville 10
Tappahannock 10
Orem 9
Tianjin 9
Amsterdam 8
Dearborn 8
Grafing 8
Guangzhou 8
Haikou 8
Mexico City 8
Norwalk 8
San Diego 8
Valsamoggia 8
Falkenstein 7
Hangzhou 7
Zhengzhou 7
Falls Church 6
Kuala Lumpur 6
Mahé 6
North York 6
Tallinn 6
Tongling 6
Turku 6
Bühl 5
Davao City 5
Istanbul 5
Johannesburg 5
São Paulo 5
Wuhan 5
Yubileyny 5
Andover 4
Bangkok 4
Totale 4.310
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 356
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 284
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 276
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 274
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 269
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 246
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy 237
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 228
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 224
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 218
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 218
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 210
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 204
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 202
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 198
Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies 196
Epigenetic regulation of nuclear inositide signalling in high-risk MDS patients 187
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 184
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 176
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes 175
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 172
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 164
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment 159
Nuclear inositide signaling in myelodysplastic syndromes. 152
Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics 142
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. 140
Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience 139
[Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering"] 129
Nelarabine Is Safe and Effective In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL): The Bologna Experience 129
NELARABINE FRONT-LINE THERAPY FOR ADULT T-LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA (T-LBL/ALL): PRELIMINARY RESULTS OF BOLOGNA EXPERIENCE 128
NELARABINE IS SAFE AND EFFECTIVE IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) AND LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 128
RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML) 126
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. 126
Nuclear translocation of PKC-alpha is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs) 120
PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment. 105
null 103
Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study 71
null 71
Totale 6.866
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.615
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.615
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022694 0 11 52 86 78 48 19 38 39 72 120 131
2022/2023881 72 127 43 114 73 65 31 92 144 9 73 38
2023/2024296 7 41 20 30 40 62 9 18 20 18 16 15
2024/2025832 36 69 71 49 173 50 53 31 3 54 52 191
2025/20262.149 193 211 170 139 246 97 227 86 393 214 81 92
2026/202758 51 7 0 0 0 0 0 0 0 0 0 0
Totale 6.866